Guest Editors:
Christopher Lord: The Institute of Cancer Research, London, UK
Timothy Yap: MD Anderson Cancer Center, US
Genome Medicine is calling for submissions to our Collection focusing on genome instability in cancer. We encourage submissions of work that expands the mechanistic knowledge of DNA damage, repair, integrity, and stability as well as research that translates these concepts to ultimately target cancer at the bedside.
Genome Medicine is calling for submissions to our Collection focusing on genome instability in cancer.
Tumor initiation, progression, and evolution are often rooted in the malfunctioning of the checkpoints securing genome integrity. Genome instability is a hallmark of cancer, and gives tumor cells many selective advantages, accelerating the evolutionary processes which allow cancers to thrive.
Maintaining the genomic machinery is not a flawless process: DNA damage, genotoxic stresses, and defects in the repair pathways can all contribute to destabilizing the complex molecular networks keeping the genome intact. Greater understanding of the biology of cancer has led, over the years, to a deeper knowledge of the mechanisms safeguarding genome stability and the many ways in which these can fail. Considering this intrinsic relationship, targeting cancer genomic instability with therapeutics has potential to improve the lives of cancer patients.
In this Collection, guest edited by Christopher Lord and Timothy Yap, we aim to highlight insights that expand upon our mechanistic knowledge of DNA damage, repair, integrity, and stability as well as research that leverages these concepts to ultimately target cancer at the bedside. We are inviting the submission of manuscripts with significant clinical and translational impact, dealing with the broader field of genome instability, including:
• DNA damage and repair;
• Responses to genotoxic stresses;
• Tumor mutation profiling and genome structural rearrangements;
• Aging, senescence, somatic mutation and their impact on cancer development;
• Diagnostic tools, risk and prognosis prediction, patient stratification;
• Response, resistance and sensitization to therapy;
• Clinical trials and models for therapeutic actionability;
• Combination approaches, including chemotherapies, radiotherapies and immunotherapies.
We encourage work that fosters academic-industry partnerships and collaboration among scientists from multi-disciplinary fields. If you would like to enquire about the suitability of a manuscript for consideration, please email editorial@genomemedicine.com.
Image credit: ktsdesign / stock.adobe.com
Dr Christopher Lord: The Institute of Cancer Research, London, UK
Chris Lord is Professor of Cancer Genomics at The Institute of Cancer Research, London. His research focusses on targeted therapies for DNA repair defective cancers, synthetic lethality and drug resistant cancers.
Dr Timothy Yap: MD Anderson Cancer Research Center, US
Dr Timothy A. Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes.
Natural killer/T cell lymphoma (NKTCL) is a clinically and genetically heterogeneous disease with poor prognosis. Genome sequencing and mutation characterization provides a powerful approach for patient strati...
Extension of prostate cancer beyond the primary site by local invasion or nodal metastasis is associated with poor prognosis. Despite significant research on tumour evolution in prostate cancer metastasis, the...
Identifying expressed somatic mutations from single-cell RNA sequencing data de novo is challenging but highly valuable. We propose RESA – Recurrently Expressed SNV Analysis, a computational framework to ident...
Clonal hematopoiesis (CH) frequently progresses after chemotherapy or radiotherapy. We evaluated the clinical impact of preoperative CH on the survival outcomes of patients with non-small cell lung cancer (NSC...
Homologous recombination is a robust, broadly error-free mechanism of double-strand break repair, and deficiencies lead to PARP inhibitor sensitivity. Patients displaying homologous recombination deficiency ca...
Prostate cancer (PrCa) genomic heterogeneity causes resistance to therapies such as androgen deprivation. Such heterogeneity can be deciphered in the context of evolutionary principles, but current clinical tr...
This Collection welcomes submission of Research, Method, Software, Database, and Guideline manuscripts. Before submitting your manuscript, please ensure you have read our submission guidelines and have formatted your submission correctly.
To submit your manuscript to this Collection, please use our online submission system and indicate in your covering letter that you would like the article to be considered for inclusion in the "Genome instability in cancer: from mechanisms to the clinic" Collection.
You are welcome to enquire about the suitability of your manuscript by emailing our editorial office at editorial@genomemedicine.com.
All articles submitted to Collections are peer reviewed in line with the journal’s standard peer review policy and are subject to all of the journal’s standard editorial and publishing policies. This includes the journal’s policy on competing interests.
The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editor or Editorial Board Member who has no competing interests.